As of 2025-10-20, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -63.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 5,562.34 mil USD. ARWR's TTM EBITDA according to its financial statements is -87.91 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 16.1x | 14.6x |
| Forward P/E multiples | 15.2x - 17.6x | 15.8x |
| Fair Price | (13.07) - (13.66) | (13.09) |
| Upside | -135.5% - -137.1% | -135.5% |
| Date | EV/EBITDA |
| 2025-10-17 | -63.27 |
| 2025-10-16 | -66.67 |
| 2025-10-15 | -65.44 |
| 2025-10-14 | -61.94 |
| 2025-10-13 | -62.39 |
| 2025-10-10 | -61.07 |
| 2025-10-09 | -62.09 |
| 2025-10-08 | -63.48 |
| 2025-10-07 | -62.85 |
| 2025-10-06 | -64.36 |
| 2025-10-03 | -62.19 |
| 2025-10-02 | -59.80 |
| 2025-10-01 | -60.44 |
| 2025-09-30 | -59.62 |
| 2025-09-29 | -58.51 |
| 2025-09-26 | -56.97 |
| 2025-09-25 | -55.17 |
| 2025-09-24 | -57.01 |
| 2025-09-23 | -56.49 |
| 2025-09-22 | -55.79 |
| 2025-09-19 | -53.65 |
| 2025-09-18 | -54.94 |
| 2025-09-17 | -51.19 |
| 2025-09-16 | -51.65 |
| 2025-09-15 | -50.47 |
| 2025-09-12 | -52.12 |
| 2025-09-11 | -52.12 |
| 2025-09-10 | -50.82 |
| 2025-09-09 | -48.99 |
| 2025-09-08 | -48.11 |
| 2025-09-05 | -51.11 |
| 2025-09-04 | -49.42 |
| 2025-09-03 | -49.10 |
| 2025-09-02 | -45.77 |
| 2025-08-29 | -40.03 |
| 2025-08-28 | -40.52 |
| 2025-08-27 | -39.65 |
| 2025-08-26 | -38.69 |
| 2025-08-25 | -37.95 |
| 2025-08-22 | -38.93 |
| 2025-08-21 | -38.01 |
| 2025-08-20 | -37.15 |
| 2025-08-19 | -36.61 |
| 2025-08-18 | -36.69 |
| 2025-08-15 | -37.64 |
| 2025-08-14 | -34.92 |
| 2025-08-13 | -36.82 |
| 2025-08-12 | -33.37 |
| 2025-08-11 | -32.45 |
| 2025-08-08 | -31.20 |